CVS Health is trading higher after the company announced on April 6, 2026 that it will hold its first-quarter 2026 earnings call on May 6, 2026 at 8:00 a.m. ET. With the next major catalyst now formally scheduled, investors are repositioning into the event as the market focuses on whether CVS can deliver against 2026 expectations across Aetna (medical cost trends) and its pharmacy-benefit manager (PBM) segment.

The stock’s upward move is being reinforced by more constructive Street messaging in recent weeks, including an Outperform upgrade and price-target increases that emphasize valuation and improving confidence in CVS’s 2026 trajectory. Recent commentary has also highlighted perceived progress toward resolving major PBM-related overhangs, which has helped reduce the discount investors have applied to the shares.

Heading into May 6, the key swing factor remains whether CVS can show improving medical-cost dynamics at Aetna while keeping PBM profitability stable as industry pricing models evolve. Investors will also be listening for any change to full-year 2026 guidance and for updated cadence assumptions (including second-half contributions) that could clarify whether current consensus expectations are too low—or too high.